[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354418-105":59,"doc-detail-354418-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cyclin-k-condensates-bridge-cdk12-to-phosphorylate-and-drive-oncogenic-yap-activation-in-hepatocellular-carcinoma","Cyclin K condensates bridge CDK12 to phosphorylate and drive oncogenic YAP activation in hepatocellular carcinoma","","Targeting transcriptional condensates is an emerging paradigm for cancer therapy. The study identifies Cyclin K as an essential vulnerability that bridges CDK12/CDK13 with the transcriptional coactivator YAP. Cyclin K/CDK12 forms a regulatory condensate that enables CDK12-mediated YAP phosphorylation, stabilizing YAP and promoting further condensation with TEAD4 to activate oncogenic programs. In hepatocellular carcinoma, coexpression predicts sensitivity to CDK12/Cyclin K inhibitors in cells and patient-derived xenografts, defining CDK12/Cyclin K–YAP axis dependence for biomarker-guided stratification.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cyclin-k-condensates-bridge-cdk12-to-phosphorylate-and-drive-oncogenic-yap-activation-in-hepatocellular-carcinoma/354418/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cyclin-k-condensates-bridge-cdk12-to-phosphorylate-and-drive-oncogenic-yap-activation-in-hepatocellular-carcinoma/354418.png","ImageObject",300,407,{"name":92,"@type":93},"Bulrr","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does Cyclin K play in YAP regulation according to the study?","Question",{"text":112,"@type":113},"Cyclin K partners with CDK12/CDK13 to bind YAP and form a regulatory condensate that enables CDK12-mediated YAP phosphorylation, stabilizing YAP and enabling oncogenic activation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is YAP phosphorylation important for oncogenic activity?",{"text":117,"@type":113},"Phosphorylation at threonine-398 prevents canonical LATS-mediated YAP inhibition, stabilizes YAP, and supports further condensation with TEAD4 to drive YAP oncogenic programs.",{"name":119,"@type":110,"acceptedAnswer":120},"How does CDK12/Cyclin K expression relate to therapy sensitivity in hepatocellular carcinoma?",{"text":121,"@type":113},"Coexpression of CDK12/Cyclin K and YAP predicts sensitivity to Cyclin K inhibitors in hepatocellular carcinoma cells and patient-derived xenografts, supporting biomarker-based patient stratification.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354418,1790177003,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","CANCER  \nCyclin K condensates bridge CDK12 to phosphorylate and drive oncogenicYAP activation in hepatocellular carcinoma  \nYang Sun1*†, Yu Zhang1†, Weikang Yan2†, Jinlin Duan3, Ke Qiao4, Guoquan Yan5, Junyan Xue1, Jie Wang1, Ming Zhan6*, Qiwei Li2*, Hongcheng Wang7*, Yonglong Zhang1,7*  \nTargeting transcriptional condensates is an emerging paradigm for cancer therapy. A key player is the transcriptional coactivator YAP (Yes-associated protein), which drives tumor-specific programs that fuel tumor progression and therapeutic resistance. Cyclin K, partnered with cyclin-dependent kinases (CDKs) CDK12/CDK13, is essential for transcription elongation, but its role in specific oncogenic programs was unclear. Here, we identify Cyclin K asan essential vulnerability across multiple cancer types. The CDK12/Cyclin K complex binds YAP via Cyclin K and forms a regulatory condensate to bridge YAP phosphorylation by CDK12. Such a phosphorylation at threonine- 398 impedes YAP inhibition by its canonical LATS kinases, stabilizes YAP, and enables its further condensation with TEAD4 to stimulate YAP oncogenic activity. Coexpression of CDK12/Cyclin K andYAP predicts sensitivity to Cyclin K inhibitors in hepatocellular carcinoma cells and patient-derived xenografts. Thus, we define CDK12/Cyclin K as a critical regulator of YAP-driven transcriptional addiction and a biomarker for patient stratification who mostly benefit from therapies targeting the CDK12/Cyclin K–YAP axis.  \ncopyright © 2026 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution license 4.0 (cc BY) .  \nINTRODUCTION  \nThe selective mRNA transcription is a fundamental biological process and is tightly controlled by the transcriptional machinery, including RNA polymerase II (Pol II), transcription factors and associated cofactors, and regulatory elements within the DNA (1, 2). Transcription is often dysregulated in diseases, including tumors (1, 3). Tumor initiates from genetic alterations that drive dysregulated transcriptional programs and establish specific transcriptional addictions to sustain numerous oncogenic phenotypes. It is thus well documented as the most fundamental feature of cancer (3–5), including hepatocellular carcinoma (HCC). Similar to cell cycle regulation, Pol II–dependent gene transcription is controlled by the concerted action of multiple transcriptional CDK-cyclin pairs, including CDK7, 8, 9, 12, and 13 and their cognate cyclins (3, 6, 7). The catalytic activity of the Pol II complex throughout transcription cycles is tightly linked to the dynamic phosphorylation of the heptad (YSPTSPS) amino acid repeats within the C-terminal domain (CTD) of the RPB1 subunit (8, 9) . Phosphorylation of serine at position 5 (S5) of the CTD is required for proper transcriptional initiation from gene promoters, whereas S2 phosphorylation promotes elongation of Pol II through the gene body and the production of mature mRNA transcript (8–11) . The transcriptional CDKs/cyclins have emerged as compelling targets  \n1laboratory of targeted therapy and Precision Medicine, department of clinical laboratory, Shanghai Jiao tong University Affiliated Sixth People’s hospital, Shanghai, china. 2department of Biliary-Pancreatic Surgery, Renji hospital, School of Medicine, Shanghai Jiao tong University, Shanghai, china. 3department of Pathology, tongren hospital Shanghai Jiaotong University School of Medicine, Shanghai, china. 4Shanghai Key laboratory of Metabolic Remodeling and health, institute of Metabolism and integrative Biology, Fudan University, Shanghai, china. 5institute of Biomedical Sciences, Shanghai Medical college, Fudan University, Shanghai, china. 6department of Systems Biology, Beckman Research institute, city of hope, Monrovia, cA 91016, USA. 7department of General Surgery, Shanghai Sixth People’s hospital Affiliated to Shanghai J","cbCaik8k4u11CEHt","https://ap.wps.com/l/cbCaik8k4u11CEHt","pdf",4824580,17,"English","# Introduction\n## Transcriptional CDK-cyclin control and Pol II phosphorylation\n## Biomolecular condensates and liquid-liquid phase separation in transcription\n## YAP hyperactivation and nuclear condensates in cancer","[{\"question\":\"What role does Cyclin K play in YAP regulation according to the study?\",\"answer\":\"Cyclin K partners with CDK12/CDK13 to bind YAP and form a regulatory condensate that enables CDK12-mediated YAP phosphorylation, stabilizing YAP and enabling oncogenic activation.\"},{\"question\":\"Why is YAP phosphorylation important for oncogenic activity?\",\"answer\":\"Phosphorylation at threonine-398 prevents canonical LATS-mediated YAP inhibition, stabilizes YAP, and supports further condensation with TEAD4 to drive YAP oncogenic programs.\"},{\"question\":\"How does CDK12/Cyclin K expression relate to therapy sensitivity in hepatocellular carcinoma?\",\"answer\":\"Coexpression of CDK12/Cyclin K and YAP predicts sensitivity to Cyclin K inhibitors in hepatocellular carcinoma cells and patient-derived xenografts, supporting biomarker-based patient stratification.\"}]","Cyclin K condensates bridge CDK12 to phosphorylate and drive oncogenic YAP activation in hepatocellular carcinoma | PDF",1790110541,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5ca2858ff53736f0dd1e27c7c9ef3c5.webp",983,1250,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b319fd776eb4409daf84b8a93c54ace1.webp",982,1249,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f24de5b41316812054dc71c3a8bb0f7.webp",981,1248,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5da61394320b1d7527bbe6e0acb7fe4c.webp",980,1247]